within Pharmacolibrary.Drugs.ATC.R;

model R07AX01
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0015,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00047999999999999996,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R07AX01</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Nitric oxide is an inhaled gas approved for the treatment of hypoxic respiratory failure in neonates and infants with pulmonary hypertension. It acts as a selective pulmonary vasodilator, improving oxygenation and decreasing the need for extracorporeal membrane oxygenation. Due to its short half-life and rapid inactivation by hemoglobin, it acts locally in the pulmonary vasculature. Nitric oxide is not used orally or intravenously, and its clinical administration is limited to controlled inhalation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are primarily determined in neonates and young children with pulmonary hypertension receiving inhaled nitric oxide; data derived from clinical use and PK estimates.</p><h4>References</h4><ol><li><p>Jomova, K, Alomar, SY, Nepovimova, E, Kuca, K, &amp; Valko, M (2025). Heavy metals: toxicity and human health effects. <i>Archives of toxicology</i> 99(1) 153–209. DOI:<a href=&quot;https://doi.org/10.1007/s00204-024-03903-2&quot;>10.1007/s00204-024-03903-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39567405/&quot;>https://pubmed.ncbi.nlm.nih.gov/39567405</a></p></li><li><p>Nagasaka, Y, Fernandez, BO, Garcia-Saura, MF, Petersen, B, Ichinose, F, Bloch, KD, Feelisch, M, &amp; Zapol, WM (2008). Brief periods of nitric oxide inhalation protect against myocardial ischemia-reperfusion injury. <i>Anesthesiology</i> 109(4) 675–682. DOI:<a href=&quot;https://doi.org/10.1097/ALN.0b013e318186316e&quot;>10.1097/ALN.0b013e318186316e</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18813047/&quot;>https://pubmed.ncbi.nlm.nih.gov/18813047</a></p></li><li><p>Abouzid, M, Roshdy, Y, Daniel, JM, Rzk, FM, Ismeal, AAA, Hendawy, M, Tanashat, M, Elnagar, M, Daoud, N, &amp; Ramadan, A (2023). The beneficial use of nitric oxide during cardiopulmonary bypass on postoperative outcomes in children and adult patients: a systematic review and meta-analysis of 2897 patients. <i>European journal of clinical pharmacology</i> 79(11) 1425–1442. DOI:<a href=&quot;https://doi.org/10.1007/s00228-023-03554-9&quot;>10.1007/s00228-023-03554-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37650923/&quot;>https://pubmed.ncbi.nlm.nih.gov/37650923</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R07AX01;
